One-year access to more than 500 world journals available in the system
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
ﻗﯿﻤﺖ
: 300$
- ﻗﯿﻤﺖ ﻭﯾﮋﻩ
: 100$
سفارش
Journals package 1months
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 31 ﺭﻭﺯ
ﻗﯿﻤﺖ
: 100$
- ﻗﯿﻤﺖ ﻭﯾﮋﻩ
: 50$
سفارش
Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis
doi : 10.1080/09546634.2024.2442720
خرید پکیج و مشاهده آنلاین مقاله